Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01955421|
Recruitment Status : Unknown
Verified July 2015 by Li Zhang, Sun Yat-sen University.
Recruitment status was: Recruiting
First Posted : October 7, 2013
Last Update Posted : July 3, 2015
|Condition or disease||Intervention/treatment||Phase|
|Advanced Stage Non Small Cell Lung Cancer||Drug: Erlotinib 100mg qd Drug: Gefitinib 250mg qd||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||224 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open-label Phase II Trial of Erlotinib 100mg Daily Versus Gefitinib 250mg Daily in Patients With Advanced Non-small Cell Lung Cancer Who Harbor EGFR Mutations.|
|Study Start Date :||July 2013|
|Estimated Primary Completion Date :||June 2016|
Patients will be randomized to buy and receive erlotinib 100mg qd.
Drug: Erlotinib 100mg qd
Patients will be randomized to buy and receive gefitinib 250mg qd.
Drug: Gefitinib 250mg qd
- disease control rate [ Time Frame: 2 years ]
- progression free survival [ Time Frame: 2 years ]
- adverse events [ Time Frame: 2 years ]rash, diarrhea, ILD, etc.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01955421
|Department of Medical Oncology, Cancer Center of Sun Yat-Sen University||Recruiting|
|Guangzhou, Guangdong, China, 510060|
|Contact: Wenhua Liang, MD 8613710249454 email@example.com|
|Principal Investigator: Li Zhang, MD|
|Sub-Investigator: Wenhua Liang, MD|